In particular, NSCLC patients with specific genetic mutations or elevated programmed cell death ligand 1 (PD-L1) expression benefit significantly from targeted therapy and immunotherapy, which have enhanced overall survival in recent years (6, 7). Here, CD274 is linked to non-small cell lung carcinoma.